Wednesday, October 26, 2011

Could RHB-104 Be The Cure For Crohn's Disease?? Very Hopeful Article

Wouldn't that be great!?? Actually curing the Crohn's!

Be encouraged and read this article, especially if you've been struggling with symptoms and just feeling blah because it's taking a toll on you. After reading this, you'll feel hopeful and optimistic about what's to come in the future and the advances that are in the making RIGHT NOW!

Even although the RHB-104 must undergo 2 years of clinical trials (US, Canada & Europe) before the drug can even be looked at by the FDA (our wonderful friends... that's sarcasm people), 2 years is nothing and will be here before we know it. Let's hope & pray that this medicine is found to be effective during the trial stage. If this RHB-104 is found to be successful, This would shed a whole new light on the disease and impact a huge population of people that suffer & struggle with Crohn's Disease everyday.

LOL is anyone else as giddy as me right now after reading that article?

Professor patents test for possible Crohn’s disease cure

The UCF Research Foundation has licensed a promising diagnostic test for the detection of the mycobacterium avium paratuberculosis, also known as MAP, bacterium in humans to an international biopharmaceutical company that is developing a treatment for Crohn's disease.
The diagnostic technology is able to diagnose MAP infection in humans using DNA testing based on nested PCR molecular technology. MAP is present in roughly 50 percent of people who suffer from Crohn's disease and could be a leading cause of the disease.
Dr. Saleh Naser, a professor in the Burnett School of Biomedical Sciences in the College of Medicine, patented the diagnostic technology in 2009 with hopes of using it to help cure Crohn's disease patients who are positive for the MAP bacterium.
Crohn's disease is an inflammatory disorder of the gastrointestinal tract affecting about 700,000 people in the United States alone, with no cure.
"Our goal with this technology is to help speed the process of diagnosing, treating patients with the correct antibiotics and helping the patient begin remission as soon as possible," Naser said. "We want to see a change in these patients' lives."
Now that RedHill Biopharma Ltd., an emerging international biopharmaceutical company, has licensed Naser's diagnostic technology, Naser is closer to achieving his goal of diagnosing and treating Crohn's disease patients.
RedHill Biopharma Ltd. is currently developing an oral drug called RHB-104, which is intended to treat and possibly cure Crohn's patients with MAP bacterium, but without a way to detect MAP, the use of the drug has been limited. Partnered with the UCF Research Foundation, RedHill Biopharma Ltd. is able to use Naser's diagnostic test to detect MAP DNA in the patient's blood and finally allow physicians to prescribe RHB-104 to Crohn's disease patients.
"Our findings in our lab since 2000 is instrumental evidence showing that MAP is a significant part of this disease, and therefore the technology to detect such pathogens is extremely useful for diagnosis and ultimately treating this disease; and with that, our partnership with RedHill is sure to be valuable," Naser said.
Under the license agreement, in consideration for an exclusive license for all indications and medical applications, RedHill Biopharma Ltd. will pay UCF an upfront payment, as well as future net sales royalties of 7 percent to 20 percent.
Despite monetary advantages, Naser is most looking forward to putting his technology to use. RedHill Biopharma Ltd. is currently in discussion with Naser regarding the use of his technology to screen Crohn's patients for MAP infection to determine whether RHB-104 would serve as an effective treatment option in two parallel placebo-controlled, double-blind clinical trials, one in the U.S. and Canada, and one in Europe.
The trials will last two years and from there, if successful, Redhill Biopharma Ltd. will bring the data to the Food and Drug Administration for approval of RHB-104, and then Naser's technology and RHB-104 could possibly be readily accessible in local labs within five years.
If available to the public, patients will first get a blood sample taken at their doctor's office, which is then sent to a local lab where the blood's white blood cells are isolated and screened for DNA of the MAP pathogen. The information from the lab will be sent back to a doctor, who can then prescribe the patient with the either RHB-104 or an antibiotic to fit the patient's needs.
This is most hard-hitting for Naser, because he knows if these trials are successful, he could impact patients' lives.
"It is hard to establish the immense amount of phone calls and emails I receive from patients and their families who are desperate to be tested for this bacteria, because what is out there is not good enough and is not helping them beat this disease," Naser said. "For the first time, we might be talking about curing Crohn's disease and not just managing the disease; the patients know the difference."
For junior language arts and English education major Molly Taylor, that difference could change her life.
Taylor has suffered from Crohn's disease for seven years, first being diagnosed in her freshman year of high school. The diagnosis forced her to quit cheerleading as she became very sick with treatment. She dropped down to weighing 85 pounds, and soon she could not even go to school; instead, she had to take online classes for a year.
After going through invasive diagnostic procedures, trying five different treatment methods and now giving herself shots every week, Taylor is thrilled about this new discovery.
"The diagnosis process has been really hard and very invasive, but this sounds like a less invasive test. Blood samples are like nothing for Crohn's patients," Taylor said. "And to have found a cure for this would be the most amazing news for me. It is hard to face a disease daily that you know is never going to go away, especially when you first find out at 15."
For research assistant Sammer Elwasila, who has been working alongside Naser since 2006, this new technology means a new beginning for Crohn's patients like Taylor, and he is excited for the chance to make a difference in people's everyday life before it is too late.
"With this technology, we hope to accomplish a clinical test that a physician can order on the spot, and that can identify and diagnose Crohn's disease patients as quickly as possible, before the damage is done," Elwasila said.

No comments:

Post a Comment